Menu Search
Equities

Universal Ibogaine Inc

JC4:DEU

Universal Ibogaine Inc

Actions
  • Price (EUR)0.014
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Universal Ibogaine Inc had revenues fall -3.81% from 1.07m to 1.03m, though the company grew net income from a loss of 10.50m to a smaller loss of 2.39m.
Gross margin28.28%
Net profit margin-66.93%
Operating margin-49.87%
Return on assets-27.90%
Return on equity-83.11%
Return on investment-35.00%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Universal Ibogaine Inc fell by 412.79k. Cash Flow from Financing totalled 1.04m or 101.42% of revenues. In addition the company used 1.10m for operations while cash used for investing totalled 360.04k.
Cash flow per share-0.0057
Price/Cash flow per share--
Book value per share0.0054
Tangible book value per share0.0054
More ▼

Balance sheet in CADView more

Universal Ibogaine Inc has a Debt to Total Capital ratio of 64.01%, a lower figure than the previous year's 114.91%.
Current ratio0.6481
Quick ratio--
Total debt/total equity1.78
Total debt/total capital0.64
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.